Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Clin Pharmacol Ther ; 99(5): 538-47, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-26566262

RESUMEN

Drug-drug interactions causing severe hypoglycemia due to antidiabetic drugs is a major clinical and public health problem. We assessed whether sulfonylurea use with a statin or fibrate was associated with severe hypoglycemia. We conducted cohort studies of users of glyburide, glipizide, and glimepiride plus a statin or fibrate within a Medicaid population. The outcome was a validated, diagnosis-based algorithm for severe hypoglycemia. Among 592,872 persons newly exposed to a sulfonylurea+antihyperlipidemic, the incidence of severe hypoglycemia was 5.8/100 person-years. Adjusted hazard ratios (HRs) for sulfonylurea+statins were consistent with no association. Most overall HRs for sulfonylurea+fibrate were elevated, with sulfonylurea-specific adjusted HRs as large as 1.50 (95% confidence interval (CI): 1.24-1.81) for glyburide+gemfibrozil, 1.37 (95% CI: 1.11-1.69) for glipizide+gemfibrozil, and 1.63 (95% CI: 1.29-2.06) for glimepiride+fenofibrate. Concomitant therapy with a sulfonylurea and fibrate is associated with an often delayed increased rate of severe hypoglycemia.


Asunto(s)
Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Hipoglucemia/inducido químicamente , Hipoglucemiantes/efectos adversos , Hipolipemiantes/efectos adversos , Anciano , Algoritmos , Estudios de Cohortes , Interacciones Farmacológicas , Femenino , Fenofibrato/administración & dosificación , Fenofibrato/efectos adversos , Glipizida/administración & dosificación , Glipizida/efectos adversos , Gliburida/administración & dosificación , Gliburida/efectos adversos , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Hipoglucemia/epidemiología , Hipoglucemiantes/administración & dosificación , Hipolipemiantes/administración & dosificación , Incidencia , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Compuestos de Sulfonilurea/administración & dosificación , Compuestos de Sulfonilurea/efectos adversos
2.
Clin Pharmacol Ther ; 99(1): 92-100, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26479278

RESUMEN

A drug-drug interaction (DDI) occurs when one or more drugs affect the pharmacokinetics (the body's effect on the drug) and/or pharmacodynamics (the drug's effect on the body) of one or more other drugs. Pharmacoepidemiologic studies are the principal way of studying the health effects of potential DDIs. This article discusses aspects of pharmacoepidemiologic research designs that are particularly salient to the design and interpretation of pharmacoepidemiologic studies of DDIs.


Asunto(s)
Interacciones Farmacológicas , Diseño de Investigaciones Epidemiológicas , Farmacoepidemiología/métodos , Humanos
3.
Diabetes Obes Metab ; 17(12): 1194-7, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26179389

RESUMEN

We conducted a population-based case-control study to assess the myocardial infarction (MI) and stroke risks associated with sulphonylureas and insulin when used in combination with metformin. Cases had type 2 diabetes and used metformin + insulin or metformin + sulphonylureas at the time of a first MI or first stroke between 1995 and 2010; controls used the same treatment combinations and were randomly sampled from the same population. MI and stroke diagnoses and potential confounders were validated by medical record reviews. Compared with metformin + sulphonylurea, metformin + insulin was associated with similar risks of MI or stroke [odds ratio 0.98 (95% confidence interval 0.63-1.52)]. Meta-analysis with another observational study improved the precision of the risk estimate [relative risk 0.92 (95% confidence interval 0.69-1.24)]. Current evidence suggests that there may not be large differences in cardiovascular risk associated with the use of insulin or sulphonylureas when used in combination with metformin.


Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Metformina/uso terapéutico , Infarto del Miocardio/prevención & control , Accidente Cerebrovascular/prevención & control , Compuestos de Sulfonilurea/uso terapéutico , Anciano , Estudios de Casos y Controles , Diabetes Mellitus Tipo 2/complicaciones , Angiopatías Diabéticas/inducido químicamente , Angiopatías Diabéticas/complicaciones , Angiopatías Diabéticas/epidemiología , Angiopatías Diabéticas/prevención & control , Cardiomiopatías Diabéticas/inducido químicamente , Cardiomiopatías Diabéticas/complicaciones , Cardiomiopatías Diabéticas/epidemiología , Cardiomiopatías Diabéticas/prevención & control , Quimioterapia Combinada/efectos adversos , Femenino , Humanos , Hipoglucemiantes/efectos adversos , Incidencia , Insulina/efectos adversos , Masculino , Registros Médicos , Metformina/efectos adversos , Persona de Mediana Edad , Infarto del Miocardio/inducido químicamente , Infarto del Miocardio/complicaciones , Infarto del Miocardio/epidemiología , Guías de Práctica Clínica como Asunto , Modelos de Riesgos Proporcionales , Factores de Riesgo , Accidente Cerebrovascular/inducido químicamente , Accidente Cerebrovascular/complicaciones , Accidente Cerebrovascular/epidemiología , Compuestos de Sulfonilurea/efectos adversos , Washingtón/epidemiología
4.
Epidemiol Infect ; 137(5): 717-26, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-18925988

RESUMEN

Demographic and clinical risk factors are important in guiding vaccination policy for pneumococcal pneumonia. We present data on these variables from a population-based surveillance network covering adult bacteraemic pneumococcal pneumonia (BPP) in the Delaware Valley region from 2002 to 2004. Surveillance data were used with U.S. Census data and a community health survey to calculate stratified incidence rates. Missing data were handled using multiple imputation. Overall rates of adult BPP were 10.6 cases/100 000 person-years. Elevated rates were seen in the elderly (>65 years), Native Americans, African Americans, the less-educated (less than high-school education), the poor, smokers, and individuals with histories of asthma, cancer, or diabetes. Multivariable modelling suggested that income was more robustly associated with risk than African American race. Of methodological interest, this association was not apparent if census block-group median income was used as a proxy for self-reported income. Further research on socioeconomic risk factors for BPP is needed.


Asunto(s)
Bacteriemia/epidemiología , Bacteriemia/microbiología , Neumonía Neumocócica/complicaciones , Neumonía Neumocócica/epidemiología , Streptococcus pneumoniae/aislamiento & purificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Etnicidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Factores de Riesgo , Factores Socioeconómicos , Estados Unidos/epidemiología , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA